Details for Patent: 9,011,905
✉ Email this page to a colleague
Which drugs does patent 9,011,905 protect, and when does it expire?
Patent 9,011,905 protects QSYMIA and is included in one NDA.
This patent has forty patent family members in seventeen countries.
Summary for Patent: 9,011,905
| Title: | Low dose topiramate/phentermine composition and methods of use thereof |
| Abstract: | A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate. |
| Inventor(s): | Najarian; Thomas (Los Osos, CA), Tam; Peter Y. (Redwood City, CA), Wilson; Leland F. (Menlo Park, CA) |
| Assignee: | Vivus, Inc. (Mountain View, CA) |
| Application Number: | 14/495,246 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,011,905 |
|
Patent Claim Types: see list of patent claims | Formulation; Dosage form; Composition; |
Drugs Protected by US Patent 9,011,905
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vivus Llc | QSYMIA | phentermine hydrochloride; topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 022580-001 | Jul 17, 2012 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Vivus Llc | QSYMIA | phentermine hydrochloride; topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 022580-002 | Jul 17, 2012 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Vivus Llc | QSYMIA | phentermine hydrochloride; topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 022580-003 | Jul 17, 2012 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Vivus Llc | QSYMIA | phentermine hydrochloride; topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 022580-004 | Jul 17, 2012 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,011,905
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2317997 | ⤷ Sign Up | CA 2021 00049 | Denmark | ⤷ Sign Up |
| European Patent Office | 2317997 | ⤷ Sign Up | CR 2021 00049 | Denmark | ⤷ Sign Up |
| European Patent Office | 2317997 | ⤷ Sign Up | 2190050-1 | Sweden | ⤷ Sign Up |
| Australia | 2009257572 | ⤷ Sign Up | |||
| Australia | 2009257573 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
